Exclusive:
India's most populous state to spend up to $1 billion to buy vaccines,
in talks with Pfizer, Sputnik V
Send a link to a friend
[May 13, 2021]
By Krishna N. Das
NEW DELHI (Reuters) - India's most populous
state of Uttar Pradesh will spend up to $1 billion to buy COVID-19 shots
and held early talks this week with companies such as Pfizer and the
local distributor of Russia's Sputnik V, a state official said on
Thursday.
|
The
move by Uttar Pradesh, home to more people than Brazil, comes as
many Indian states curtail vaccinations due to severe shortages amid
a record surge in coronavirus infections, with India recording more
than 4,000 deaths for a second straight day as its health system
fails to cope.
Uttar Pradesh has also held pre-bid talks with Indian vaccine
companies the Serum Institute of India - licensed to make the
AstraZeneca and Novavax shots - Bharat Biotech and Cadila Healthcare
as part of a global tender to buy 40 million doses over the next few
months, state spokesman Navneet Sehgal told Reuters.

He said Johnson and Johnson could also confirm their participation
in the tender by late Thursday via email. Sputnik V's local
distributor, Dr. Reddy's Laboratories, has also held talks.
[to top of second column] |

"Money is not an issue, we have a huge budget," said Sehgal, a
senior bureaucrat in the state of 240 million people. "We will spend
up to 100 billion rupees ($1.36 billion)."
He however said funds would have to be diverted from other areas to
buy the vaccines.
(Reporting by Krishna N. Das; Additional reporting by Aishwarya
Nair; Editing by Nick Macfie)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |